The relative safety of biologic drugs used in the treatment of inflammatory bowel diseases

Kliknij autora aby wyszukać wszystkie publikowane przez niego artykuły:
Paweł Moćko

1 (54) 2018 s. 135–140
Click to return to issue contents
Digital version of article (in PDF file)


Fraza do cytowania: Moćko P. The relative safety of biologic drugs used in the treatment of inflammatory bowel diseases. Polski Przegląd Nauk o Zdrowiu. 2018;1(54):135–140. DOI:

Crohn's disease (CD) and ulcerative colitis (UC) are two the most common inflammatory bowel diseases (IBD) which are illnesses of unknown etiology and complex multifactorial pathogenesis. In the treatment of IBD various therapeutic options could be used including biologic drugs. One of the most essential threats generated by the use of biologic drugs is a high risk of infections. Moreover, some authors suggest that biologics may contribute to the development of tumors. The aim of the study was to present the current state of knowledge with regard to the comparison of safety profile of each individual biologic drug used in the therapy of patients with IBD. We identified five studies relating to comparison of the safety profile between the biologic drugs: two studies in a population of patients with UC, two in CD patients and one describing the pooled results for patients with IBD. All identified studies were systematic reviews of randomized clinical trials with network meta-analysis, while only three studies included probability analysis of being the safest treatment option i.e. rank analysis. Review revealed a very small number of studies relating to discussed issues. What's more, only three studies provided a detailed analysis of the safety profile of biologic drugs. In summary, the analysis, in particular the results of analysis that included ranks estimation indicated the missing data on the relative assessment of biologic drugs used to treat patients with IBD. It should be noted the need of further research and analysis to confirm the results.

Key words: Crohn's disease, CD, ulcerative colitis, UC, biological agents, safety profile.

Copyright © 1989–2020 Polish Review of Health Sciences. All rights reserved.